Adenosine receptor antagonists (especially non-selective A2A receptor antagonists, such as methylxanthines, caffeine, or selective A2A antagonists) have been shown to enhance therapeutic effect of l-DOPA in a wide range of animal models of PD [118–121]. This evidence concerns the gene IGKV2D-29 and Parkinson disease.